HC Wainwright set a $8.00 price target on T2 Biosystems (NASDAQ:TTOO) in a research note published on Wednesday. The brokerage currently has a buy rating on the medical equipment provider’s stock.
Several other research analysts have also recently issued reports on the company. Goldman Sachs Group initiated coverage on T2 Biosystems in a research note on Monday, January 29th. They issued a neutral rating and a $5.20 price objective on the stock. Zacks Investment Research raised T2 Biosystems from a hold rating to a buy rating and set a $4.75 price objective on the stock in a research note on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $5.56.
Shares of T2 Biosystems (TTOO) traded up $0.42 during trading hours on Wednesday, reaching $6.80. The company had a trading volume of 830,971 shares, compared to its average volume of 404,296. T2 Biosystems has a 52 week low of $2.50 and a 52 week high of $6.99. The company has a current ratio of 5.40, a quick ratio of 5.28 and a debt-to-equity ratio of 2.25.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Gagnon Securities LLC bought a new stake in T2 Biosystems during the 3rd quarter valued at $396,000. Lagoda Investment Management L.P. boosted its position in T2 Biosystems by 61.4% during the 3rd quarter. Lagoda Investment Management L.P. now owns 3,188,539 shares of the medical equipment provider’s stock valued at $13,392,000 after acquiring an additional 1,212,618 shares in the last quarter. Senvest Management LLC boosted its position in T2 Biosystems by 17.6% during the 3rd quarter. Senvest Management LLC now owns 3,337,946 shares of the medical equipment provider’s stock valued at $14,019,000 after acquiring an additional 500,000 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in T2 Biosystems during the 3rd quarter valued at $630,000. Finally, Renaissance Technologies LLC boosted its position in T2 Biosystems by 72.2% during the 4th quarter. Renaissance Technologies LLC now owns 83,500 shares of the medical equipment provider’s stock valued at $344,000 after acquiring an additional 35,000 shares in the last quarter. 52.61% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “T2 Biosystems (TTOO) Given a $8.00 Price Target by HC Wainwright Analysts” was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3254003/t2-biosystems-ttoo-given-a-8-00-price-target-by-hc-wainwright-analysts.html.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.